Missing In Action: China’s Best Shot In Ebola Vaccine Race
As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?
You may also be interested in...
Following reports of another Ebola outbreak in Africa, Scrip explores the pipeline of clinical-stage vaccines and how the companies developing immunizations are approaching the most recent cases of the viral hemorrhagic disease.
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.